Influenza: Evolving Strategies in Treatment and Prevention

Joseph P. Lynch; Edward E. Walsh

doi:10.1055/s-2007-976487

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2007; 28(2): 144-158
DOI: 10.1055/s-2007-976487

Influenza: Evolving Strategies in Treatment and Prevention

Joseph P. Lynch¹ III , Edward E. Walsh²

¹Division of Pulmonary, Critical Care Medicine, and Hospitalists, Department of Internal Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California
²Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York

Abstract

ABSTRACT

Influenza A and B are important causes of respiratory illness in all age groups. Influenza causes seasonal outbreaks globally, and (rarely) pandemics. In the United States, seasonal influenza epidemics account for > 200,000 hospitalizations and > 30,000 deaths annually. More than 90% of deaths are in the elderly. The toll is considerably higher during pandemics. Clinical features of influenza infection overlap with other respiratory pathogens (particularly viruses). The diagnosis is often delayed due to low suspicion and the limited use of specific diagnostic tests. Rapid diagnostic tests are widely available and allow detection of influenza antigen in respiratory secretions within 1 hour; however, sensitivity ranges from 40 to 80%. Currently, four drugs are available to treat or prevent influenza. These include the adamantanes (i.e., amantadine and rimantadine) and the neuraminidase inhibitors (i.e., oseltamivir and zanamivir). Adamantanes are active against influenza A but not influenza B. However, recent emergence of adamantane resistance has rendered these agents ineffective. Hence, adamantanes are not currently recommended in the United States. The neuraminidase inhibitors (NAIs) are effective in treating influenza A or B, and for prophylaxis in selected adults and children. Resistance to NAIs is rare, but influenza strains resistant to oseltamivir have been detected. Vaccines are the cornerstone of influenza control. Currently, trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV) are available. These agents reduce mortality and morbidity in high-risk patients (i.e., the elderly or patients with comorbidities), and expanding the use of vaccines to healthy children and adults reduces the incidence of influenza, pneumonia, and hospitalizations due to respiratory illnesses in the community.

KEYWORDS

Influenza A and B - epidemics - pandemics - adamantanes - neuraminidase inhibitors - vaccination

Full Text

References

REFERENCES

1 Petric M, Comanor L, Petti C A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics. J Infect Dis. 2006; 194(Suppl 2) S98-S110
2 Bright R A, Medina M J, Xu X et al.. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005; 366 1175-1181
3 Nichol K L, Treanor J J. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006; 194(Suppl 2) S111-S118
4 Neuzil K M, Zhu Y, Griffin M R et al.. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002; 185 147-152
5 Chew F T, Doraisingham S, Ling A E, Kumarasinghe G, Lee B W. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect. 1998; 121 121-128
6 Sugawa N, Mitamura K, Yamazaki M et al.. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007; 44 197-202
7 Kawai N, Ikematsu H, Iwaki N et al.. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis. 2005; 40 1309-1316
8 Glezen W P, Couch R B. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med. 1978; 298 587-592
9 Fox J P, Cooney M K, Hall C E, Foy H M. Influenzavirus infections in Seattle families, 1975-1979, II: Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol. 1982; 116 228-242
10 Thompson W W, Comanor L, Shay D K. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis. 2006; 194(Suppl 2) S82-S91
11 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289 179-186
12 Osterholm M T. Preparing for the next pandemic. N Engl J Med. 2005; 352 1839-1842
13 Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002; 76 105-115
14 Rajagopal S, Treanor J. Pandemic (avian) influenza. Semin Respir Crit Care Med. 2007; 28 159-170
15 Poehling K A, Edwards K M, Weinberg G A et al.. The underrecognized burden of influenza in young children. N Engl J Med. 2006; 355 31-40
16 Whitley R J, Monto A S. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006; 194(Suppl 2) S133-S138
17 Whimbey E, Elting L S, Couch R B et al.. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994; 13 437-440
18 Nichols W G, Guthrie K A, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004; 39 1300-1306
19 Kim Y-J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007; 28 222-242
20 Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006; 193 760-764
21 Murata Y, Walsh E, Falsey A. Pulmonary complications of inter-pandemic influenza A in hospitalized patients. J Infect Dis. 2007; 195 1029-1037
22 Kobasa D, Takada A, Shinya K et al.. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004; 431 703-707
23 Louria D B, Blumenfeld H L, Ellis J T, Kilbourne E D, Rogers D E. Studies on influenza in the pandemic of 1957-1958, II: Pulmonary complications of influenza. J Clin Invest. 1959; 38(1 Part 2) 213-265
24 O'Brien K L, Walters M I, Sellman J et al.. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis. 2000; 30 784-789
25 Fainstein V, Musher D M, Cate T R. Bacterial adherence to pharyngeal cells during viral infection. J Infect Dis. 1980; 141 172-176
26 Edelen J S, Bender T R, Chin T D. Encephalopathy and pericarditis during an outbreak of influenza. Am J Epidemiol. 1974; 100 79-84
27 Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003; 36 299-305
28 Morishima T, Togashi T, Yokota S et al.. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002; 35 512-517
29 Starko K M, Ray C G, Dominguez L B, Stromberg W L, Woodall D F. Reye's syndrome and salicylate use. Pediatrics. 1980; 66 859-864
30 Belay E D, Bresee J S, Holman R C, Khan A S, Shahriari A, Schonberger L B. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. 1999; 340 1377-1382
31 Englund J A, Champlin R E, Wyde P R et al.. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998; 26 1418-1424
32 Hirschhorn L R, McIntosh K, Anderson K G, Dermody T S. Influenzal pneumonia as a complication of autologous bone marrow transplantation. Clin Infect Dis. 1992; 14 786-787
33 Ljungman P, Andersson J, Aschan J et al.. Influenza A in immunocompromised patients. Clin Infect Dis. 1993; 17 244-247
34 Apalsch A M, Green M, Ledesma-Medina J, Nour B, Wald E R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients. Clin Infect Dis. 1995; 20 394-399
35 Neuzil K M, Reed G W, Mitchel E F, Simonsen L, Griffin M R. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998; 148 1094-1102
36 O'Brien M A, Uyeki T M, Shay D K et al.. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004; 113(3 Pt 1) 585-593
37 Grijalva C G, Craig A S, Dupont W D et al.. Estimating influenza hospitalizations among children. Emerg Infect Dis. 2006; 12 103-109
38 Izurieta H S, Thompson W W, Kramarz P et al.. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000; 342 232-239
39 Meltzer M I, Neuzil K M, Griffin M R, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine. 2005; 23 1004-1014
40 Neuzil K M, Mellen B G, Wright P F, Mitchel Jr E F, Griffin M R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000; 342 225-231
41 Bhat N, Wright J G, Broder K R et al.. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005; 353 2559-2567
42 Walsh E E, Cox C, Falsey A R. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc. 2002; 50 1498-1503
43 Uyeki T M. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003; 22 164-177
44 Weinberg G A, Erdman D D, Edwards K M et al.. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis. 2004; 189 706-710
45 Bonner A B, Monroe K W, Talley L I, Klasner A E, Kimberlin D W. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial. Pediatrics. 2003; 112 363-367
46 Sharma V, Dowd M D, Slaughter A J, Simon S D. Effect of rapid diagnosis of influenza virus type a on the emergency department management of febrile infants and toddlers. Arch Pediatr Adolesc Med. 2002; 156 41-43
47 Poehling K A, Griffin M R, Dittus R S et al.. Bedside diagnosis of Influenzavirus infections in hospitalized children. Pediatrics. 2002; 110(1 Pt 1) 83-88
48 Couch R B. Prevention and treatment of influenza. N Engl J Med. 2000; 343 1778-1787
49 Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005; 353 1363-1373
50 Wang C, Takeuchi K, Pinto L H, Lamb R A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993; 67 5585-5594
51 Bright R A, Shay D K, Shu B, Cox N J, Klimov A I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006; 295 891-894
52 High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006; 55 44-46
53 Smith N M, Bresee J S, Shay D K, Uyeki T M, Cox N J, Strikas R A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-10) 1-42
54 Monto A S, Ohmit S E, Hornbuckle K, Pearce C L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother. 1995; 39 2224-2228
55 Younkin S W, Betts R F, Roth F K, Douglas Jr R G. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983; 23 577-582
56 Dolin R, Reichman R C, Madore H P, Maynard R, Linton P N, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982; 307 580-584
57 Brady M T, Sears S D, Pacini D L et al.. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother. 1990; 34 1633-1636
58 Reuman P D, Bernstein D I, Keefer M C, Young E C, Sherwood J R, Schiff G M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res. 1989; 11 27-40
59 Van Voris L P, Betts R F, Hayden F G, Christmas W A, Douglas Jr R G. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981; 245 1128-1131
60 Monto A S, Gunn R A, Bandyk M G, King C L. Prevention of Russian influenza by amantadine. JAMA. 1979; 241 1003-1007
61 Patriarca P A, Kater N A, Kendal A P, Bregman D J, Smith J D, Sikes R K. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes. Antimicrob Agents Chemother. 1984; 26 101-103
62 Galbraith A W, Oxford J S, Schild G C, Watson G I. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet. 1969; 2 1026-1028
63 Hayden F G, Belshe R B, Clover R D, Hay A J, Oakes M G, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989; 321 1696-1702
64 Keyser L A, Karl M, Nafziger A N, Bertino Jr J S. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med. 2000; 160 1485-1488
65 Weinstock D M, Zuccotti G. Adamantane resistance in influenza A. JAMA. 2006; 295 934-936
66 Hall C B, Dolin R, Gala C L et al.. Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987; 80 275-282
67 Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med. 1995; 155 533-537
68 Belshe R B, Burk B, Newman F, Cerruti R L, Sim I S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989; 159 430-435
69 Prud'homme I T, Zoueva O, Weber J M. Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991-94. Clin Diagn Virol. 1997; 8 41-51
70 Ilyushina N A, Govorkova E A, Webster R G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virology. 2005; 341 102-106
71 Rodriguez W J, Hall C B, Welliver R et al.. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr. 1994; 125 129-135
72 Knight V, McClung H W, Wilson S Z et al.. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981; 2 945-949
73 Gilbert B E, Wilson S Z, Knight V et al.. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985; 27 309-313
74 Oxford J, Balasingam S, Lambkin R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J Antimicrob Chemother. 2004; 53 133-136
75 Cooper N J, Sutton A J, Abrams K R, Wailoo A, Turner D, Nicholson K G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003; 326 1235
76 Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 2002; 54 143-147
77 Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Saf. 1999; 21 267-281
78 Hayden F G, Belshe R, Villanueva C et al.. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004; 189 440-449
79 McClellan K, Perry C M. Oseltamivir: a review of its use in influenza. Drugs. 2001; 61 263-283
80 Hayden F G, Pavia A T. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006; 194(Suppl 2) S119-S126
81 Treanor J J, Hayden F G, Vrooman P S et al.. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000; 283 1016-1024
82 Nicholson K G, Aoki F Y, Osterhaus A D et al.. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000; 355 1845-1850
83 Aoki F Y, Macleod M D, Paggiaro P et al.. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003; 51 123-129
84 Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003; 163 1667-1672
85 Hedrick J A, Barzilai A, Behre U et al.. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000; 19 410-417
86 Bowles S K, Lee W, Simor A E et al.. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc. 2002; 50 608-616
87 Nordstrom B L, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005; 21 761-768
88 Whitley R J, Hayden F G, Reisinger K S et al.. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20 127-133
89 Hayden F G, Atmar R L, Schilling M et al.. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999; 341 1336-1343
90 Welliver R, Monto A S, Carewicz O et al.. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001; 285 748-754
91 Monto A S, Rotthoff J, Teich E et al.. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis. 2004; 39 459-464
92 Peters Jr P H, Gravenstein S, Norwood P et al.. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001; 49 1025-1031
93 Rothberg M B, Bellantonio S, Rose D N. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003; 139(5 Pt 1) 321-329
94 Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet. 1998; 352 1877-1881
95 Monto A S, Pichichero M E, Blanckenberg S J et al.. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002; 186 1582-1588
96 de Jong M D, Tran T T, Truong H K et al.. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353 2667-2672
97 Hayden F G, Osterhaus A D, Treanor J J et al.. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of Influenzavirus infections. GG167 Influenza Study Group. N Engl J Med. 1997; 337 874-880
98 Monto A S, Fleming D M, Henry D et al.. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 1999; 180 254-261
99 Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. 2001; 161 212-217
100 Kaiser L, Keene O N, Hammond J M, Elliott M, Hayden F G. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med. 2000; 160 3234-3240
101 Makela M J, Pauksens K, Rostila T et al.. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000; 40 42-48
102 Matsumoto K, Ogawa N, Nerome K et al.. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antivir Ther. 1999; 4 61-68
103 Monto A S, Robinson D P, Herlocher M L, Hinson Jr J M, Elliott M J, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999; 282 31-35
104 Hayden F G, Gubareva L V, Monto A S et al.. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000; 343 1282-1289
105 Cass L M, Gunawardena K A, Macmahon M M, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med. 2000; 94 166-173
106 Gubareva L V, Kaiser L, Hayden F G. Influenza virus neuraminidase inhibitors. Lancet. 2000; 355 827-835
107 McKimm-Breschkin J, Trivedi T, Hampson A et al.. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003; 47 2264-2272
108 Moscona A. Oseltamivir-resistant influenza?. Lancet. 2004; 364 733-734
109 Moscona A. Oseltamivir resistance-disabling our influenza defenses. N Engl J Med. 2005; 353 2633-2636
110 Brett A S, Zuger A. The run on Tamiflu-should physicians prescribe on demand?. N Engl J Med. 2005; 353 2636-2637
111 Yen H L, Herlocher L M, Hoffmann E et al.. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother. 2005; 49 4075-4084
112 Stilianakis N I, Perelson A S, Hayden F G. Drug resistance and influenza pandemics. Lancet. 2002; 359 1862-1863
113 Kiso M, Mitamura K, Sakai-Tagawa Y et al.. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004; 364 759-765
114 Beigel J H, Farrar J, Han A M et al.. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005; 353 1374-1385
115 Le Q M, Kiso M, Someya K et al.. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005; 437 1108
116 Carr J, Ives J, Kelly L et al.. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002; 54 79-88
117 Ives J A, Carr J A, Mendel D B et al.. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002; 55 307-317
118 Gubareva L V, Matrosovich M N, Brenner M K, Bethell R C, Webster R G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998; 178 1257-1262
119 Lee T H. Rationing influenza vaccine. N Engl J Med. 2004; 351 2365-2366
120 Schwartz B, Hinman A, Abramson J et al.. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J Infect Dis. 2006; 194(Suppl 2) S147-S154
121 Schmidt A. Progress in respiratory virus vaccine development. Semin Respir Crit Care Med. 2007; 28 243-252
122 Fukuda K, Kieny M P. Different approaches to influenza vaccination. N Engl J Med. 2006; 355 2586-2587
123 Recommended composition of influenza virus vaccines for use in the 2004-2005 influenza season. Wkly Epidemiol Rec. 2004; 79 88-92
124 Bridges C B, Thompson W W, Meltzer M I et al.. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000; 284 1655-1663
125 Ohmit S E, Victor J C, Rotthoff J R et al.. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006; 355 2513-2522
126 Harper S A, Fukuda K, Uyeki T M, Cox N J, Bridges C B. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005; 54(RR-8) 1-40
127 Small Jr P A, Bender B S. Vaccination against influenza in healthy adults. N Engl J Med. 1996; 334 402-403 , author reply 3-4
128 Nichol K L, Lind A, Margolis K L et al.. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995; 333 889-893
129 Nichol K L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med. 2001; 161 749-759
130 Demicheli V, Rivetti D, Deeks J J, Jefferson T O. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004; (3) CD001269
131 Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med. 1995; 123 518-527
132 Ohmit S E, Arden N H, Monto A S. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc. 1999; 47 165-171
133 Potter J, Stott D J, Roberts M A et al.. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997; 175 1-6
134 Wilde J A, McMillan J A, Serwint J, Butta J, O'Riordan M A, Steinhoff M C. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999; 281 908-913
135 Pearson M L, Bridges C B, Harper S A. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-2) 1-16
136 Carman W F, Elder A G, Wallace L A et al.. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 2000; 355 93-97
137 Burls A, Jordan R, Barton P et al.. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine. 2006; 24 4212-4221
138 Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine. 2002; 20 1831-1836
139 Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005; 366 1165-1174
140 Nichol K L, Margolis K L, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994; 331 778-784
141 Fedson D S, Wajda A, Nicol J P, Hammond G W, Kaiser D L, Roos L L. Clinical effectiveness of influenza vaccination in Manitoba. JAMA. 1993; 270 1956-1961
142 Foster D A, Talsma A, Furumoto-Dawson A et al.. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol. 1992; 136 296-307
143 Arden N, Monto A S, Ohmit S E. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. Am J Public Health. 1995; 85 399-401
144 Monto A S, Hornbuckle K, Ohmit S E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001; 154 155-160
145 Nichol K L, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003; 348 1322-1332
146 Mullooly J P, Bennett M D, Hornbrook M C et al.. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med. 1994; 121 947-952
147 Nichol K L, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998; 158 1769-1776
148 Hak E, Buskens E, van Essen G A et al.. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med. 2005; 165 274-280
149 Nichol K L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999; 130 397-403
150 Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet. 2005; 365 773-780
151 Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine. 2005; 23 2851-2861
152 Hurwitz E S, Haber M, Chang A et al.. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000; 284 1677-1682
153 Reichert T A, Sugaya N, Fedson D S, Glezen W P, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med. 2001; 344 889-896
154 Piedra P A, Gaglani M J, Kozinetz C A et al.. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005; 23 1540-1548
155 Monto A S, Davenport F M, Napier J A, Francis Jr T. Modification of an outbreak of influenza in Tecumseh, Michigan, by vaccination of schoolchildren. J Infect Dis. 1970; 122 16-25
156 Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child. 1991; 145 445-448
157 Weller S C, Mann N C. Influenza vaccination and acute otitis media in children. Am J Dis Child. 1992; 146 1018-1019
158 Clements D A, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med. 1995; 149 1113-1117
159 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children. N Engl J Med. 1998; 338 1405-1412
160 Podewils L J, Liedtke L A, McDonald L C et al.. A national survey of severe influenza-associated complications among children and adults, 2003-2004. Clin Infect Dis. 2005; 40 1693-1696
161 Brownstein J S, Kleinman K P, Mandl K D. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. Am J Epidemiol. 2005; 162 686-693
162 King Jr J C, Stoddard J J, Gaglani M J et al.. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006; 355 2523-2532
163 Jordan R, Connock M, Albon E et al.. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine. 2006; 24 1047-1062
164 Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1990; 39(RR-7) 1-15
165 Influenza vaccination levels in selected states: Behavioral Risk Factor Surveillance System, 1987. MMWR Morb Mortal Wkly Rep. 1989; 38 124, 9-33
166 Prevention and control of influenza, I: Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1994; 43(RR-9) 1-13
167 Bridges C B, Winquist A G, Fukuda K, Cox N J, Singleton J A, Strikas R A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000; 49(RR-3) 1-38 , quiz CE1-7
168 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-9) 1-25
169 Bridges C B, Fukuda K, Uyeki T M, Cox N J, Singleton J A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002; 51(RR-3) 1-31
170 Hemingway C O, Poehling K A. Change in recommendation affects influenza vaccinations among children 6 to 59 months of age. Pediatrics. 2004; 114 948-952
171 Arden N H. Control of influenza in the long-term-care facility: a review of established approaches and newer options. Infect Control Hosp Epidemiol. 2000; 21 59-64
172 Estimated influenza vaccination coverage among adults and children: United States, September 1, 2004-January 31, 2005. MMWR Morb Mortal Wkly Rep. 2005; 54 304-307
173 Nichol K L, Margolis K L, Lind A et al.. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med. 1996; 156 1546-1550
174 Margolis K L, Nichol K L, Poland G A, Pluhar R E. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA. 1990; 264 1139-1141
175 James J M, Zeiger R S, Lester M R et al.. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr. 1998; 133 624-628
176 Hurwitz E S, Schonberger L B, Nelson D B, Holman R C. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med. 1981; 304 1557-1561
177 Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al.. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979; 110 105-123
178 Marks J S, Halpin T J. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA. 1980; 243 2490-2494
179 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998; 339 1797-1802
180 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998; 47(RR-6) 1-26
181 Nichol K L, Mendelman P M, Mallon K P et al.. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999; 282 137-144

Joseph P Lynch IIIM.D.

Division of Pulmonary, Critical Care Medicine, and Hospitalists, The David Geffen School of Medicine at UCLA

10833 Le Conte Ave., Rm. CHS 37-131, Los Angeles, CA 90095

Email: jplynch@mednet.ucla.edu